Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

ImmunoPrecise Antibodies Ltd. (IPA) had Revenue of $18.16M for the most recently reported fiscal year, ending 2024-04-30.

Quarterly Annual

Figures for fiscal year ending 2024-04-30

Income Statement Financials
Revenue	$18.16M
Net Income	$-20.13M
Cost of Goods Sold	$9.23M
Gross Profit	$8.93M
Operating Expenses	$28.60M
Operating Income	$-10.44M
Non-Operating Income/Expense	$-10.82M
Pre-Tax Income	$-21.26M
Normalized Pre-Tax Income	$-10.13M
Income after Taxes	$-20.13M
Income from Continuous Operations	$-20.13M
Consolidated Net Income/Loss	$-20.13M
Normalized Income after Taxes	$-8.40M
EBIT	$-10.44M
EBITDA	$-6.19M
Weighted-Average Shares Outstanding (Basic)	25.64M
Weighted-Average Shares Outstanding (Diluted)	25.64M
Earnings per Share (EPS) (Basic)	$-0.79
Earnings per Share (EPS) (Diluted)	$-0.79
Balance Sheet Financials
Current Assets	$8.51M
Property, Plant, and Equipment	$12.37M
Long-Term Assets	$35.92M
Total Assets	$44.43M
Current Liabilities	$6.02M
Long-Term Debt	$8.97M
Long-Term Liabilities	$13.29M
Total Liabilities	$19.31M
Common Equity	$25.12M
Tangible Shareholders Equity	$1.98M
Shareholders Equity	$25.12M
Common Shares Outstanding	26.95M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-3.14M
Cash Flow from Investing Activities	$-1.16M
Cash Flow from Financial Activities	$0.76M
Beginning Cash	$6.20M
End Cash	$2.63M
Increase/Decrease in Cash	$-3.57M
Stock-Based Compensation	$1.14M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.41
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.26
Debt to Equity Ratio	0.40
Gross Margin	49.16%
Operating Margin	-57.48%
EBIT Margin	-57.48%
EBITDA Margin	-34.09%
Pre-Tax Profit Margin	-117.07%
Profit Margin	-110.85%
Free Cash Flow	$-4.18M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.41
Inventory Turnover	5.83
Receiveable Turnover	5.83
Days Sales in Receivables	62.59
Return on Equity	-80.12%
Return on Tangible Equity	-1015.20%
Return on Assets	-45.30%
Return on Investments	-59.03%
Book Value Per Share	$0.93
Free Cash Flow per Share	$-0.16
Operating Cash Flow per Share	$-0.12

Data from Zacks Investment Research, Inc.